# Public summary document

**Product:** Corstop Hydrogel Stoma Stopper Dressing

**Applicant:** Avanos Medical Australia PTY LTD

**Date of SPAP Meeting:** 26 April 2022

## Proposed Deletion on the Stoma Appliance Scheme

The applicant, Avanos Medical Australia PTY LTD, sought the deletion of all variants from the current listing of Corstop Hydrogel Stoma Stopper Dressing (SAS Code 80164E) in subgroup 9(l) of the Stoma Appliance Scheme (SAS) Schedule, as it is no longer being manufactured. The product, including one variant, is currently listed at a unit price of $4.532 with a maximum monthly quantity of 30 units.

## Substitute products

Not applicable.

## Variants to be deleted

| **Product Code** | **Description** |
| --- | --- |
| CS-01 | RESTRICTED Hydrogel dressing, R1 |

## Background

This product was first listed on the SAS Schedule on 1 May 2018.

## Clinical Place for the Product

Not applicable.

## Financial Analysis

The deletion of the entire product range is recommended. It is therefore unlikely that there would be any budgetary impact for the SAS as a consequence of deleting this product.

## Panel Recommendation

The Panel recommended the deletion of the entire product range for Corstop Hydrogel Stoma Stopper Dressing (SAS Code 80164E) listed in subgroup 9(l) of the SAS Schedule at the unit price of $4.532, with a maximum monthly quantity of 30 units.

The Panel also noted that Avanos Medical Australia PTY LTD is to advise Stoma Associations, ostomates, Stomal Therapy Nurses and ACSA of the deletion. A period of approximately six months from the Panel recommended date (26 April 2022) should be given to allow users of the product to seek a suitable alternative and to enable Stoma Associations to manage their stock levels.

## Context for Recommendation

The Panel provides advice on whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. Applications are considered in this context. Panel advice not to recommend listing or changes to a listing does not represent a final Panel view about the merits of a particular stoma product. A company can resubmit to the Panel following advice not to recommend listing or changes to a listing. The Panel is an advisory committee and as such its recommendations are non-binding on Government. All Panel recommendations are subject to Cabinet/Ministerial approval.

## Applicant’s Comment

The applicant noted the SPAP recommendation.